Compare Amcor PLC (AMCR) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amcor PLC vs BridgeBio Pharma Inc — how do they compare? Amcor PLC trades at $47.5 (market cap $21.78B), while BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B). The key difference: Amcor PLC is the larger of the two by market cap, and Amcor PLC pays a 5.52% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| AMCR | BBIO | |
|---|---|---|
Market Cap | $21.78B | $16.61B |
Sector | Basic Materials | Health |
52-Week High | $50.58 | $90.17 |
52-Week Low | $36.69 | $47.29 |
Enterprise Value | $36.90B | $18.16B |
Dividend Yield | 5.52% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amcor PLC
Amcor is a global plastics packaging behemoth, with global sales of USD 14.5 billion in fiscal 2022 following the acquisition of Bemis in 2019. Amcor's operations span over 40 countries globally and include significant emerging-market exposure equating to circa 20% of sales. Amcor's capabilities span flexible and rigid plastic packaging, which sell into defensive food, beverage, healthcare, household, and personal-care end markets.
Read more on AMCR →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
